Efficacy of needle-free injection on antibody production against Clostridium chauvoei in beef calves under field conditions.

This study compared needle-free and needle-based injection devices for vaccination of calves against Clostridium chauvoei in warm and cold conditions. Both devices elicited comparable antibody responses in calves. Needle-free injection devices can be used to vaccinate calves provided appropriate precautions are taken in cold weather.

Efficacité de l'injection sans seringue sur la production d'anticorps contreClostridium chauvoeichez les veaux de boucherie dans des conditions sur le terrain. Cette étude a comparé les dispositifs à injection sans seringue et avec seringue pour la vaccination des veaux contre Clostridium chauvoei dans des conditions par temps chaud et froid. Les deux dispositifs ont provoqué des réponses comparables des anticorps chez les veaux. Des dispositifs d'injection sans seringue peuvent être utilisés pour vacciner les veaux pourvu que des précautions appropriées soient prises par temps froid.(Traduit par Isabelle Vallières).

A study of the effectiveness of a needle-free injection device compared with a needle and syringe used to vaccinate calves against bovine viral diarrhea and infectious bovine rhinotracheitis viruses.

The aim of this study was to compare the effectiveness of a needle-free injection device (NF) with a needle and syringe (NS) when used to vaccinate calves against bovine viral diarrhea virus (BVDV) and infectious bovine rhinotracheitis virus (IBRV). The study was conducted in two independent phases. Ninety-six crossbred beef calves were vaccinated in the spring and 98 beef calves in the autumn. The calves were vaccinated using a NF or NS at 2 months of age (day 0) and again on day 119, with a modified-live virus vaccine containing IBRV, BVDV (types 1 and 2), parainfluenza-3 virus, and bovine respiratory syncytial virus. In each herd 10 calves were left unvaccinated to determine whether exposure to either BVDV or IBRV occurred. Visible vaccine residue at the surface of the skin/hair was apparent immediately following vaccination with NF in 30% of the spring-born calves following both the primary and booster vaccination. In the autumn, visible vaccine residues occurred in 19% and 8% of NF-vaccinated calves following the primary and booster vaccination. Post-vaccination skin reactions recorded on days 21, 42, 119 and 140 occurred with greater frequency in NF-vaccinated calves than NS-vaccinated ones. Blood samples were collected on days 0, 21, 42, 119, and 140 and tested for antibodies to BVDV and IBRV. Vaccination technique had no significant effect on BVDV or IBRV antibody concentrations at any time point. NF was as effective as NS vaccination in eliciting BVDV and IBRV antibody responses.

The global eradication of poliomyelitis: progress and problems.

Encouraged by the success of the global smallpox eradication certified in 1980, the global poliomyelitis eradication program was launched in 1988 by the World Health Organization (WHO). In addition to routine polio immunization included in the Expanded Program of Immunization (EPI), two major activities were planned: mass polio vaccination campaigns and surveillance of all cases of acute flaccid paralysis. In 2000, the disease had been eliminated from most countries in the world. However, as of 2002, the community acceptance of vaccination was endangered in some countries by rumors about assumed adverse effects of oral polio vaccine. The rejection of polio immunization provided a worrying resurgence of polio in Northern Nigeria, followed by re-infection of 21 countries, whereas resurgence of the disease also was observed in Northern India. Supplementary vaccination activities were resumed, additional resources were mobilized and, in 2007, most re-infected countries became polio-free again. Today, polio remains endemic in only four countries. The goal of global polio eradication has now been set at 2010, but doubts have been expressed about the feasibility of its achievement.